Study on the Third or Fourth Line-Therapy of unresectable locally advanced or metastatic Renal Cell Carcinoma An open, randomized Phase-III-Trial with MK-6482 versus Everolimus in Participants with advanced Renal Cell Carcinoma that showed Tumor Progression after previous PD-1/L1 and VEGF-targeted Therapies (HIF-005) - AUO-No. AN 51/19